Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MTNB vs CORT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CORT Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

CORT Overall Winner 6-Pillar Tally: MTNB 0 – 5 CORT (1 Tie) Matrix Metrics: MTNB 1 – 9 CORT

As of Nov 19, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas CORT carries 43.9/100 (HOLD) at $64.98 (13.0x Forward P/E, 11.5% operating margin).

  • Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. CORT 43.9/100 HOLD), CORT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (11.5% vs. 0.0% operating margin) and revenue trajectory (+64.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile CORT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MTNB vs CORT
MTNB NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47
CORT NASDAQ Head-to-Head Winner
Corcept Therapeutics Inc.
Pharmaceutical Preparations
$64.98
-4.15% 1D
Market Cap $7.4B
TTM Revenue $964M
Forward P/E 13.0x
Beta / 30D Vol 1.62β · 81% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 25.0 Fund 56.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.6%), weak momentum, RSI 22
RSI-14: 21.7 · SMA20: $77.08 · SMA50: $100.01

6-Pillar Scorecard Institutional Category Breakdown (MTNB 0 – 5 CORT)

Columns: Metric · MTNB · CORT
1. Valuation Multiples CORT
Forward P/E N/M 13.0x
Trailing P/E N/M 51.0x
PEG Ratio N/M 0.81x
EV / Revenue N/M 7.6x
2. Growth & Scale CORT
Revenue Growth (YoY) -100.0% +64.0%
Earnings Growth (YoY) +0.0% +531.3%
TTM Revenue (USD) N/A $964M
Market Cap $979,904 $7.4B
3. Profitability & Quality CORT
Gross Margin N/A 98.5%
Operating Margin 0.0% 11.5%
Net Profit Margin 0.0% 16.8%
Return on Equity (ROE) -147.5% 22.1%
4. Balance Sheet & Cash Flow CORT
Cash Generation (TTM) N/A $195M
Cash Flow Margin N/A 20.2%
Net Cash / Leverage $1.2M Net Cash $90M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CORT
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 73.1% (19th %ile)
Put/Call OI Skew N/A 1.76x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MTNB (1) vs CORT (9)
Institutional Metric MTNB CORT Criterion Row Edge
Market Capitalization
Scale
$979,904 $7.4B Larger Scale CORT
Trailing P/E Ratio
Valuation
N/M 51.0x Lower Multiple CORT
Forward P/E Ratio
Valuation
N/M 13.0x Lower Multiple CORT
Revenue Growth (YoY)
Growth
-100.0% +64.0% Higher Growth CORT
Operating Margin (TTM)
Profitability
0.0% 11.5% Higher Margin CORT
Net Profit Margin
Profitability
0.0% 16.8% Higher Margin CORT
Return on Equity (ROE)
Capital Efficiency
-147.5% 22.1% Higher ROE CORT
52-Week Range Position
Momentum
22% ($0–$3) 37% ($29–$126) Stronger Trend CORT
Beta / 30D Volatility
Risk Regime
-7.20β · 147% Vol 1.62β · 81% Vol Lower Realized Risk CORT
Unified Institutional Score
Composite Signal
54.6 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
N/A $964M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 98.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.81x PEG · 7.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.2M Net Cash) $195M ($90M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CORT +2.58 pp
MTNB: -46.7% · CORT: -44.12%
3M Horizon MTNB +354.34 pp
MTNB: +307.49% · CORT: -46.85%
6M Horizon MTNB +12.07 pp
MTNB: +20.93% · CORT: +8.86%
1Y Horizon CORT +17.86 pp
MTNB: -31.35% · CORT: -13.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MTNB Revenue CORT Revenue MTNB Op. Margin CORT Op. Margin Margin Leader
FY2018 $0M $250M -12230.9% 35.6% CORT
FY2019 $0M $310M -21067.4% 36.4% CORT
FY2020 $0M $350M -15288.4% 36.2% CORT
FY2021 $0M $370M -74954.5% 34.0% CORT
FY2022 $0M $400M -771.3% 28.0% CORT
FY2023 $0M $480M -2168.4% 22.2% CORT
FY2024 N/A $680M N/A 20.3% CORT
FY2025 N/A $760M N/A 5.9% CORT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CORT CONSOLIDATION
112d in phase · OBV DISTRIBUTION
Current IV 73.1%
IV Percentile 19th %ile
Put/Call OI Skew 1.76x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CORT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $69.22 · IV 95.3%

CORT Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($6,922)

Compare $6,922 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 95.3% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $75 / $85 Bull Call Spread

Buy 1x $75C · Sell 1x $85C · 32d

Net Entry $280 Debit
T+5d @ +5% Move +$46 (+16%)
Max Risk / Buffer $280 Capped
5d Edge & Liquidity 0.6x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $60 / $55 Bull Put Spread

Sell 1x $60P · Buy 1x $55P · 32d

Net Entry $175 Credit
Max Credit / Yield +$175 (+53.8% RoM)
Max Risk / Buffer -15.8% Cushion ($325 Mgn)
5d Edge & Liquidity 73% PoP · Liq B
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $60P / $75-$85C Seagull

Sell 1x $60P · Buy 1x $75/$85C · 32d

Net Entry $190 Credit
T+5d @ +5% Move +$217 (+24.6% RoM)
Max Risk / Buffer -13.3% Put Cushion ($880 Mgn)
5d Edge & Liquidity 1.5x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CORT Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $7.4B market capitalization and 11.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MTNB vs CORT Key Questions & Quantitative Answers

As of Nov 19, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas CORT carries 43.9/100 (HOLD) at $64.98 (13.0x Forward P/E, 11.5% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. CORT 43.9/100 HOLD), CORT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (11.5% vs. 0.0% operating margin) and revenue trajectory (+64.0% vs. -100.0% YoY). Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile CORT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CORT leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CORT at +64.0% YoY revenue growth and +531.3% YoY earnings growth on $964M TTM revenue (98.5% gross margin, 11.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MTNB cumulative revenue shifted N/A while CORT shifted +204.0%. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CORT.

CORT screens cheaper on headline valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CORT trades at 13.0x Forward P/E, 51.0x Trailing P/E, 0.81x PEG, and 7.6x EV/Revenue (20.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus CORT (22.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, CORT carries 73.1% implied volatility (19th %ile, Compressed (<25th %ile)), a 1.76x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.62β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.